Investigational drug Dupixent (dupilumab) for ages 6 to adult.
Trial Criteria
This trial tests the use of dupilumab (Dupixent) for the treatment of alopecia areata.
- Enrolled patients are to be from age 6+. For patients age 6-17, we require an overall minimum of 30% hair loss from the scalp, and for patients age 18+ we require an overall minimum of 50% hair loss from the scalp.
- Patients are required to have a personal history of atopic disease (history of allergies, asthma, or eczema).
- Patients should not have tried Dupixent before.
- Patients are to self-administer subcutaneous injections of Dupixent weekly and return to our clinic every 8-12 weeks throughout the study.
Of note, there is a 33% chance of being randomized into a placebo group, but after 48 weeks everyone in the study is guaranteed to be receiving Dupixent.
General Information
Below is general information for alopecia areata studies at Mount Sinai.
- All patient data is anonymized, maintained strictly confidential, and restricted to the research office at the Department of Dermatology at Mount Sinai.
- Patients are compensated for their time in our studies upon completion.
- Patient data is aggregated and intended to be published in medical literature at a future time which could be one or more years from now.
- During visits, patients’ alopecia will be assessed, standard blood draws are done (not every visit), and medication will be administered and renewed.
- Each study has specific criteria including age, gender and duration of alopecia.
Patient Visit Location
Department of Dermatology
Icahn School of Medicine at Mount Sinai
5 East 98th Street, 5th Floor
New York, NY 10029
Contact
For anyone interested in participating in one of our studies, we would love the opportunity to discuss further. We can be reached at (212) 241-3288, or at ariel.azhdam@mountsinai.org or hannah.malinosky@mountsinai.org.
Thank you ~ Dr. Ariel Azhdam and Dr. Hannah Malinosky